Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
IPO Year:
Exchange: NYSE
Website: smith-nephew.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/25/2025 | Buy → Hold | HSBC Securities | |
| 3/12/2025 | Buy → Neutral | UBS | |
| 11/6/2024 | Buy → Hold | Berenberg | |
| 11/1/2024 | Buy → Hold | Deutsche Bank | |
| 7/24/2024 | Buy | Deutsche Bank | |
| 6/5/2024 | Neutral → Buy | UBS | |
| 11/28/2023 | Underweight → Equal Weight | Barclays | |
| 11/3/2023 | Neutral → Overweight | JP Morgan | |
| 10/31/2023 | Hold → Buy | HSBC Securities | |
| 10/13/2023 | Hold | Stifel |
HSBC Securities downgraded Smith & Nephew from Buy to Hold
UBS downgraded Smith & Nephew from Buy to Neutral
Berenberg downgraded Smith & Nephew from Buy to Hold
Deutsche Bank downgraded Smith & Nephew from Buy to Hold
Deutsche Bank initiated coverage of Smith & Nephew with a rating of Buy
UBS upgraded Smith & Nephew from Neutral to Buy
Barclays upgraded Smith & Nephew from Underweight to Equal Weight
JP Morgan upgraded Smith & Nephew from Neutral to Overweight
HSBC Securities upgraded Smith & Nephew from Hold to Buy
Stifel initiated coverage of Smith & Nephew with a rating of Hold
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee. As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value. Ajay's experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy
STAUNTON, Va., Sept. 12, 2024 /PRNewswire/ -- Cadence, Inc., a leading provider of vertically integrated contract manufacturing solutions to the MedTech and Pharma markets, is pleased to announce the appointment of Bob White to its Board of Directors. Mr. White brings over 25 years of business leadership experience and a proven track record in operational excellence, technological innovation, and strategic growth to Cadence. Mr. White has demonstrated exceptional skills in managing global locations, having held senior positions at Medtronic, GE Healthcare, and IBM. He recent
New York, United States, March 03, 2025 (GLOBE NEWSWIRE) -- The global demand for wound care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Download Free Sample Report PDF @ https://straitsresearc
New York, United States, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The global demand for Wound Care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Get a Free Sample Copy of This Report https://stra
Adds two close-to-market innovative technologies to Healiva's® growing portfolio of end-to-end care for chronic wounds Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed. The first asset, EpiDex®, is an
LONDON, Jan. 19, 2022 /PRNewswire/ -- Smith+Nephew ((LSE: SN, NYSE:SNN), the global medical technology business, announces the acquisition of Engage Surgical, owner of the only cementless unicompartmental (partial) knee system commercially available in the US. This acquisition strongly supports Smith+Nephew's strategy for growth by transforming its business through innovation and acquisition, while also providing differentiation for its customers. The Engage Surgical Partial Knee System is a novel, modern cementless knee implant to serve a resurgent segment driven by the poten
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches at The Championships, Wimbledon in 2025. The world's oldest and most prestigious tennis tournament serves as a perfect backdrop to showcase Smith+Nephew's purpose of ‘Life Unlimited' - making a difference in patients' lives through the excellence of a diverse Sports Medicine product portfolio and the application of new technologies. Tennis is a high-impact sport that places great stress on various areas of the body – especially joints – often resulting in injury. Some of the latest technologies and solutions from Smith+Nephew for joint re
The future of fracture fixation with novel side-specific nails featuring variable angle locking technology Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new TRIGEN MAX Tibia Nailing System for stable and unstable fractures of the tibia, including the shaft. It is the only system to now offer trauma surgeons the choice of side-specific (right and left) nails for anatomic screw trajectories, which help to optimize fragment fixation and minimize soft tissue irritation with headless and low-profile screw options.1, 2 The TRIGEN MAX Tibia Nailing System aims to streamline operative procedures and provide efficiency through surgeon-ce
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee. As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value. Ajay's experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces a strategic partnership with Standard Health www.standardhealth.co.uk to support the development of the first-ever Orthopaedic Ambulatory Surgery Centre in the UK. Based in Poole, Dorset, the new centre will offer NHS and private patients access to leading joint repair and replacement technology for conditions such as rotator cuff repair, ACL reconstruction, knee and hip replacements, and foot & ankle/hand & wrist procedures. Standard Health is a clinical healthcare provider, responsible for site development and operation of the facility with Smith+Nephew supplying its innovative portfolio of medical t
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized inserts are seeing a steep rise in popularity, growing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023.1 With the ability to be used with or without the Posterior Cruciate Ligament (PCL), procedural trends are moving away from Posterior Stabilized (PS) design types to more bone-conservative Cruciate Retaining (CR) femoral designs. The reduction of operating steps also creates the potential for greater efficiency and shorter time in the OR for both surgeon and patient.2 Th
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, has been selected to provide its RENASYS◊ TOUCH Negative Pressure Wound Therapy (NPWT) Systems under a single award, 10-year* contract for up to $75 million by the U.S. Department of Defense (DoD) through the Defense Logistics Agency (DLA). The RENASYS TOUCH NPWT System demonstrated clinical efficacy,1,2,3,4 and operational fitness including portability,2 an intuitive interface,5,6,7 and the ability to provide a range of therapy modes, set points and cycle times that allow individualized patient care. The system will support military medical providers to administer therapy through prolonged casualty care, first surgic
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in Caesarean section (C-section) recovery has identified significant benefits for postpartum use of Smith+Nephew's leading PICO sNPWT technology. Analyzing real-world data from over 10,000 C-section patients treated at different pressure levels, the study published in WOUNDS (April 2025) reveals that PICO sNPWT contributes to a significant reduction in surgical site complications (SSCs), including a reduction in the incidence of surgical site infections (SSIs), wound dehiscence and seroma, and
The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces encouraging results for its CARTIHEAL AGILI-C Cartilage Repair Implant from a recent multicentre randomised controlled trial (RCT) treating knee cartilage defects. When compared to the current surgical standard of care,* the implant demonstrated: Superior pain relief: Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 4-year period.1-3 ** Superior functional gains: Patients treated with the
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB:AURX) ("Nuo"), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced it has entered into an exclusive private label distribution agreement ("Agreement") with global medical technology company Smith+Nephew ((LSE:SN, NYSE:SNN). Under the Agreement, Smith+Nephew will market and sell CENTRIO Platelet-Rich Plasma System, their own branded version of Nuo's underlying Aurix® System to the United States wound care market. Nuo will continue to be responsible for manufacturing the product. The Aurix product
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include: Robotics: Optimizing and personalizing surgery With CORIOGRAPH◊ Pre-Op Planning and Modeling Services advanced technology and the CORI Surgical System's image-agnostic solution for robotic-assisted knee and computer-guided hip replacement procedures, Smith+Nephew offers a highly personalized approach for both surgeons and their patients. CORIOGRAPH's recent addition of support for hip procedures
3 - SMITH & NEPHEW PLC (0000845982) (Reporting)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
SD - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
SC 13D - SMITH & NEPHEW PLC (0000845982) (Subject)
SC 13G/A - SMITH & NEPHEW PLC (0000845982) (Subject)